Meeting Tue, 04/16/2024 - 12:00 Drug Prior Authorization Committee Meeting Information

Date
Media
MO Pharmacy Advisory Boards Slides April 2024
PDL Recommendations April 2024
PDL Announcements July 2024
Edit Implementation Schedule through August 2024
Conduent Reports April 2024
Conduent Reports Helpdesk and POS April 2024
Conduent Reports Top 25 April 2024
New Drugs April 2024
Agenda
DPAC Agenda April 2024
Minutes
DPAC Minutes April 2024 Approved
Criteria
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Givlaari April 2024
Imcivree April 2024
Megestrol Acetate April 2024
Nulibry April 2024
Scenesse April 2024
Spravato April 2024
Zokinvy April 2024
DUR Criteria
Clinical and Fiscal Edits- New or Revised of Existing Criteria
Media
Acne or Rosacea Select Topical April 2024
Antifungals Systemic April 2024
Fabry Disease April 2024
GABAA Modulators for PPD April 2024
Isturisa April 2024
Oxervate April 2024
Pompe Disease April 2024
Prior Auth Required Fiscal Edit April 2024
Voxzogo April 2024
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Actinic Keratosis Agents, Topical April 2024
Androgenic Agents April 2024
Antibiotics, Inhaled April 2024
Anticholinergics, Long Acting Beta Adrenergic (LABA) Combinations April 2024
Anticholinergics, Short Acting and Combinations Inhaled April 2024
Antifungals (Onychomycosis/Candidiasis), Oral April 2024
Antifungals, Topical April 2024
Antihistamines and Antihistamine/Decongestant Combinations, 2nd Generation April 2024
Antihistamines, Intranasal April 2024
Antihistamines, Ophthalmic April 2024
Antiparasitics, Topical April 2024
Antivirals, Herpes Oral April 2024
Antivirals, Topical April 2024
Beta Adrenergic, Long Acting April 2024
Beta Adrenergic, Nebulized April 2024
Corticosteroids, Ophthalmic “Soft” April 2024
Corticosteroids, Topical April 2024
Fluoroquinolones, Ophthalmic April 2024
Leukotriene Receptor Modifiers April 2024
Mast Cell Stabilizers, Ophthalmic April 2024
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Ophthalmic April 2024
Pancreatic Enzyme Agents April 2024
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Anticholinergics, Long Acting Beta Adrenergics (LABA)/ Inhaled Corticosteroid (ICS) Combinations and Phosphodiesterase 4 (PDE4) Inhibitors April 2024
Anticholinergics, Long Acting Inhaled April 2024
Benzoyl Peroxide/Antibiotic Combinations April 2024
Beta Adrenergic Agents, Short Acting April 2024
Corticosteroids & Rhinitis Agents, Intranasal April 2024
Corticosteroids, Oral Inhaled April 2024
Cough and Cold Preparations April 2024
Epinephrine Agents, Self-Injectable April 2024
Fluoroquinolones, Otic April 2024
Gene Therapies for Sickle Cell Disease and Beta-Thalassemia April 2024
Glaucoma Agents April 2024
Hepatitis C Agents April 2024
Inflammatory Bowel Disease Agents, Oral April 2024
Inflammatory Bowel Disease Agents, Rectal April 2024
Retinoids, Topical April 2024
Page
Drug Prior Authorization Committee Meeting Information